### List of abstracts included in the review

| 4. | A. Soto Gonzalez DBG, M. Buño Soto, M. Lopez De La Torre Casares. The liraglutide leads to not only improve glycemic control, but also cause liver inflammation of nonalcoholic fatty liver disease patients. 2013. |


25. Fernandez Garcia JC, Cortes Salazar, C.M, Aranda, P. Liraglutide decreases microalbuminuria and blood pressure in hypertensive obese patients with type 2 diabetes. Journal of...


40. JEAN-FRANÇOIS GAUTIER AP, GUILLAUME CHARPENTIER, AMIRA BOUZIDI, SULIYA MADANI, LUC MARTINEZ, EVELINE ESCHWÈGE, PIERRE GOUR. The Proportion of Patients Successfully Treated with Liraglutide—Results from a Post-hoc Analysis of the EVIDENCE Study. 2015.

41. JUAN J. GORGOJO-MARTINEZ CS-M, GARA FEO-ORTEGA. Effect of Renal Impairment on the Effectiveness and Safety of Two GLP-1 Receptor Agonists, Exenatide, and Liraglutide in Patients with Type 2 Diabetes. Presented at the ADA, Boston, June 6-9, 2015.

42. K. Nakamura AY, K. Nakata. Fasting serum C-peptide and age is a useful predictor of successful liraglutide monotherapy in Japanese type 2 diabetes patients. 2013.


46. Lecube A, Gutierrez L, Lopez C, Sanchez E. What Happened with Patients Who Initiated Treatment with the Human GLP-1 Analogue Liraglutide More than 2 Years Ago? Diabetes. 2015;64.

47. Lecube A, Gutierrez L, Lopez C, Sanchez E. What Happened with Patients Who Initiated Treatment with the Human GLP-1 Analogue Liraglutide More than 2 Years Ago? Presented at The American Diabetes Association (ADA) 75th Scientific Sessions., June 5 - 9, 2015; Boston, Massachusetts. 2015.


Effectiveness of switching from a DPP-4 inhibitor to the human GLP-1 analogue liraglutide in patients with type 2 diabetes: Data from the EVIDENCE study. Diabetologia. 2014;57(1):S1-S566.


60. OSHINOBU KONDO SS, URI NEZU. OSADA, YASUO TERAUCHI. Exenatide BID Improves B-Cell Function More than Liraglutide QD in Patients with Type 2 Diabetes: A Propensity Score Matched Retrospective Cohort Study (ELENA-B). 2015.


76. Thayer S, Wei W, Brekke L, Buysman E, Hu W, Cuddihy R. How different were they? A retrospective study of real-world U.S. Patients with Type 2 Diabetes Mellitus ( T2DM ) Initiating once-daily injectable pen therapy with insulin glargine or liraglutide. Endocrine Reviews. 2012;33(3).


